Celcuity INC. (CELC) — 10-K Filings
All 10-K filings from Celcuity INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Celcuity Advances Gedatolisib with Key Clinical Milestones, FDA Designations
— Mar 26, 2026 Risk: high
Celcuity Inc. (CELC) is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumor indications. Their lead candidate, gedat -
Celcuity Inc. Files 2024 10-K Report
— Mar 31, 2025 Risk: medium
Celcuity Inc. filed its 2024 10-K report on March 31, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, based -
Celcuity Inc. Files 2023 Annual Report on Form 10-K
— Mar 27, 2024 Risk: medium
Celcuity Inc. (CELC) filed a Annual Report (10-K) with the SEC on March 27, 2024. Celcuity Inc. filed its 2023 Form 10-K on March 27, 2024, reporting on the fis
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX